United Therapeutics officer proposes $4.69M stock sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
United Therapeutics Corp. officer Paul Mahon gave notice of a proposed sale of 8,300 common shares, with an approximate sale date of November 19, 2026, and an aggregate market value of $4,690,228.74. The notice records August 11, 2025, as the date of plan adoption or instruction if relying on Rule 10b5-1. It also lists six prior sales of 8,300 shares each, from August 20 through November 5, 2026.
Key Figures
Key Terms
Rule 10b5-1 regulatory
stock option exercise financial
aggregate market value financial
gross proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.